Sygnature Discovery collaborates with DaltonTxto advance AI-enabled drug discovery capabilities

Nottingham, UK – 4 June 2026 – Sygnature Discovery, a leading integrated drug discovery contract research organisation (CRO), has announced a strategic collaboration with DaltonTx an AI-technology company, to further strengthen its AI-enabled drug discovery capabilities and accelerate medicinal chemistry decision-making while safeguarding customer data.

DaltonTx combines expertise in drug discovery, software engineering and artificial intelligence through its Dalton platform, which integrates data, models and experimental results into a single learning system to support biologics and small molecule discovery programmes.

The collaboration brings DaltonTx into Sygnature Discovery’s existing computational and medicinal chemistry toolkit alongside proprietary and third-party technologies including SygDesign, BullFrog AI and Iktos. By combining multiple complementary AI platforms, Sygnature Discovery aims to support faster, more informed decision-making across discovery programmes.

As part of the collaboration, Sygnature Discovery is conducting a retrospective evaluation using a legacy oncology programme focused on a small molecule clinical candidate now in Phase I development. The analysis is assessing whether the platform could have enabled the team to reach candidate selection more efficiently through improved decision-making and reduced synthesis burden.

“AI in drug discovery continues to evolve rapidly, but we believe the future lies in combining the power of machine learning with the expertise and intuition of experienced scientists,” said Simon Hirst, CEO of Sygnature Discovery. “By helping scientists make better-informed decisions earlier in the discovery process, we can reduce the number of compounds synthesised and tested, shorten DMTA cycles and accelerate progression toward candidate selection.”

Unlike many standalone AI applications, Dalton combines a secure and scalable backend architecture with a natural language interface powered by agentic AI technologies, enabling scientists to drive ideation and problem-solving through conversational workflows.

“The next phase of AI in drug discovery is about impact,” said Garry Pairaudeau, CEO and Co-Founder of DaltonTx. “We believe the organisations that capture the most value from AI will be those that connect their teams, tools and data into systems that improve real-world discovery decisions. Dalton unifies data, models, and experimental results to capture what worked, what failed and why, with full context so judgement compounds over time. We are proud to collaborate with Sygnature Discovery to deliver tangible outcomes that translate into measurable value.”

The collaboration also addresses growing industry concerns surrounding proprietary data use in AI-enabled environments. Sygnature Discovery confirmed that customer data and AI models are compartmentalised on a per-programme basis to ensure customer information is not used to train models supporting other projects.

“Our approach ensures customers can access the latest AI-enabled technologies without their data being used to train models for the benefit of others,” added Hirst. “We have mature systems in place for securely managing customer data, and those same principles apply when deploying AI tools.”

Sygnature Discovery intends to extend validation of the Dalton platform into live customer programmes as opportunities arise.

ENDS

About Sygnature Discovery

At Sygnature Discovery, we create exceptional scientific outcomes. For our customers, who bring life-changing medicines to patients; and for our people, who help make this possible.

We’re 700+ scientists from over 50 countries, working as one across Europe and North America. With no competing internal programs, we offer total confidentiality and commitment.

Over the past 20+ years, we’ve earned a track record of real impact: 60+ advanced candidates, 200+ patents filed, 200+ active projects. Over 90% of our customers choose to stay with us – from biotechs racing to clinic to pharma companies that need specialised expertise for targeted challenges.

www.sygnaturediscovery.com

About DaltonTx

DaltonTx is building the intelligence backbone for modern drug discovery, combining AI, human expertise, and experimental data into one continuous learning engine. 

The Dalton platform works across the entire drug discovery process for small molecules and biologics. It captures what worked, what failed and why, with full context and perfect memory so judgement compounds over time. Agents propose strategies, evaluate trade-offs, and autonomously orchestrate a comprehensive suite of AI, physics and ML tools and models.

The outcome is smarter decisions, fewer wasted experiments, and the confidence to tackle more complex biology, knowing that every cycle improves the next choice.

Founded on research from the University of Oxford and built by leaders with decades of experience behind AI discovery platforms at AstraZeneca and Exscientia, DaltonTx delivers state of the art scientific AI with secure, enterprise quality engineering.

For more information please contact:

Optimum Strategic Communications

Nick Bastin, Eleanor Cooper, Henry Williams

Tel: +44 20 4604 4016

Email: daltontx@optimumcomms.com